Danish bank cuts Genmab price target, retains "buy" recommendation
Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.
by marketwire, translated by daniel pedersen
Danish bank Jyske bank has cut Genmab’s share price target by 4 percent, going from DKK 2975 (USD 453.5) to DKK 2850 (USD 434.4). The bank retains its recommendation ”buy” despite the company’s recent dip on the exchange, according to an analysis prior to the company’s financial report, which will be publicized on February 16.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen applies for FDA approval for Genmab drug
For subscribers
.jpg)
.jpg&w=384&q=75)
